Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 243-258 , April 2008

Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications

  • Elahe A. Mostaghel, MD, PhD (Research Associate in Clinical Research Division)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 206 667 3506; Fax: +1 206 667 2917.
    • ,
  • Peter S. Nelson, MD (Member in Human Biology Division)

References 

  1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA: A Cancer Journal for Clinicians. 1972;22(4):232–240
  2. Forti G, Salerno R, Moneti G, et al. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content. The Journal of Clinical Endocrinology and Metabolism. 1989;68(2):461–468
  3. Mohler JL, Gregory CW, Ford OH, et al. The androgen axis in recurrent prostate cancer. Clinical Cancer Research. 2004;10(2):440–448
  4. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clinical Cancer Research. 2004;10(21):7121–7126
  5. Geller J, Liu J, Albert J, et al. Relationship between human prostatic epithelial cell protein synthesis and tissue dihydrotestosterone level. Clinical Endocrinology. 1987;26(2):155–161
  6. Scher HI, Buchanan G, Gerald W, et al. Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer. Endocrine-Related Cancer. 2004;11(3):459–476
  7. Belanger B, Belanger A, Labrie F, et al. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: Unique importance of extratesticular androgens in men. Journal of Steroid Biochemistry. 1989;32(5):695–698
  8. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Research. 2006;66(5):2815–2825
  9. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. American Journal of Pathology. 2004;164(1):217–227
  10. Liu J, Geller J, Albert J, et al. Acute effects of testicular and adrenal cortical blockade on protein synthesis and dihydrotestosterone content of human prostate tissue. The Journal of Clinical Endocrinology and Metabolism. 1985;61(1):129–133
  11. Labrie F, Dupont A, Belanger A, et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. Journal of Steroid Biochemistry. 1985;23(5B):833–841
  12. Page ST, Lin DW, Mostaghel EA, et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. The Journal of Clinical Endocrinology and Metabolism. 2006;91(10):3850–3856
  13. Mizokami A, Koh E, Fujita H, et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Research. 2004;64(2):765–771
  14. Nishiyama T, Ikarashi T, Hashimoto Y, et al. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score. The Journal of Urology. 2007;178(4 Pt 1):1282–1288[discussion 1288–1289]
  15. Montgomery B, Mostaghel E, Vessella R, et al. Androgen synthesis in castration-adapted metastatic prostate cancer. ASCO Annual Meeting Proceedings 2007;Part 1. Journal of Clinical Oncology. 2007;25(No. 18S):98
  16. Gregory CW, Johnson RT, Mohler JL, et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Research. 2001;61(7):2892–2898
  17. van Weerden WM, van Steenbrugge GJ, van Kreuningen A, et al. Effects of low testosterone levels and of adrenal androgens on growth of prostate tumor models in nude mice. The Journal of Steroid Biochemistry and Molecular Biology. 1990;37(6):903–907
  18. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Research. 2007;67(10):5033–5041
  19. Ryan CJ, Smith A, Lal P, et al. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. Urology. 2006;68(4):834–839
  20. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nature Medicine. 2004;10(1):33–39
  21. Small EJ, Ryan CJ. The case for secondary hormonal therapies in the chemotherapy age. The Journal of Urology. 2006;176(6):S66–S71
  22. Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002;95(2):361–376
  23. Klotz L, Schellhammer P. Combined androgen blockade: the case for bicalutamide. Clinical Prostate Cancer. 2005;3(4):215–219
  24. Labrie F. Adrenal androgens and intracrinology. Seminars in Reproductive Medicine. 2004;22(4):299–309
  25. Bruchovsky N. Comparison of the metabolites formed in rat prostate following the in vivo administration of seven natural androgens. Endocrinology. 1971;89(5):1212–1222
  26. Schiller CD, Schneider MR, Hartmann H, et al. Growth-stimulating effect of adrenal androgens on the R3327 dunning prostatic carcinoma. Urological Research. 1991;19(1):7–13
  27. Harper ME, Pike A, Peeling WB, et al. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. The Journal of Endocrinology. 1974;60(1):117–125
  28. Klein H, Bressel M, Kastendieck H, et al. Androgens, adrenal androgen precursors, and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer. American Journal of Clinical Oncology. 1988;11(Suppl. 2):S30–S36
  29. Miyamoto H, Yeh S, Lardy H, et al. Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(19):11083–11088
  30. Acevedo HF, Goldzieher JW. The metabolism of [14C] progesterone by hypertrophic and carcinomatous human prostate tissue. Biochimica et Biophysica Acta. 1965;111(1):294–298
  31. Attard G, Yap TA, Reid AH, et al. Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (a), in castration refractory prostate cancer (CRPC) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor. ASCO Annual Meeting Proceedings 2007;Part 1. Journal of Clinical Oncology. 2007;25(No. 18S):5063
  32. Auchus RJ. The backdoor pathway to dihydrotestosterone. Trends in Endocrinology and Metabolism. 2004;15(9):432–438
  33. Luo J, Dunn TA, Ewing CM, et al. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma. Prostate. 2003;57(2):134–139
  34. Titus MA, Gregory CW, Ford OH, et al. Steroid 5{alpha}-reductase isozymes I and II in recurrent prostate cancer. Clinical Cancer Research. 2005;11(12):4365–4371
  35. Thomas LN, Douglas RC, Lazier CB, et al. Levels of 5[alpha]-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. The Journal of Urology. 2008;179(1):147–151
  36. Koh E, Noda T, Kanaya J, et al. Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate. 2002;53(2):154–159
  37. Fung KM, Samara EN, Wong C, et al. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocrine-Related Cancer. 2006;13(1):169–180
  38. Zha S, Ferdinandusse S, Hicks JL, et al. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate. 2005;63(4):316–323
  39. Penning TM, Bauman DR, Jin Y, et al. Identification of the molecular switch that regulates access of 5[alpha]-DHT to the androgen receptor. Adrenal/Molecular Steroidogenesis Conference 2006. Molecular and Cellular Endocrinology. 2007;265–266:77–82
  40. Ji Q, Chang L, Stanczyk FZ, et al. Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling. Cancer Research. 2007;67(3):1361–1369
  41. Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU International. 2005;96(9):1241–1246
  42. Handratta VD, Vasaitis TS, Njar VCO, et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: Synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. Journal of Medicinal Chemistry. 2005;48(8):2972–2984
  43. O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. British Journal of Cancer. 2004;90(12):2317–2325
  44. Ryan CJ, Rosenberg J, Lin A, et al. Phase I evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-lyase inhibitor in androgen-independent prostate cancer (AIPC). ASCO Annual Meeting Proceedings 2007;Part 1. Journal of Clinical Oncology. 2007;25(No. 18S):5064
  45. Ryan CJ, Halabi S, Ou SS, et al. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: Results from a Cancer and Leukemia Group B study. Clinical Cancer Research. 2007;13(7):2030–2037
  46. Culig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Molecular Endocrinology. 1993;7(12):1541–1550
  47. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). Journal of Clinical Oncology. 2004;22(6):1025–1033
  48. Berube M, Laplante Y, Poirier D. Design, synthesis and in vitro evaluation of 4-androstene-3,17-dione/adenosine hybrid compounds as bisubstrate inhibitors of type 3 17beta-hydroxysteroid dehydrogenase. Medicinal Chemistry. 2006;2(4):329–347
  49. Lorenzi MV, Rizzo CA, You D, et al. In vivo suppression of testosterone biosynthesis with a novel series of non-steroidal 17{beta}-hydroxysteroid dehydrogenase type III (17{beta}-HSD3) inhibitors. In: Proceedings of the 96th annual meeting of the American Association for Cancer Research; 2005 April 1. p. 605-a. [Abstract 2573].
  50. Bauman DR, Rudnick SI, Szewczuk LM, et al. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: Potential antineoplastic agents that work independently of cyclooxygenase isozymes. Molecular Pharmacology. 2005;67(1):60–68
  51. Byrns MC, Steckelbroeck S, Penning TM. An indomethacin analogue, n-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochemical Pharmacology. 2008;75(2):484–493
  52. Krazeisen A, Breitling R, Moller G, et al. Phytoestrogens inhibit human 17[beta]-hydroxysteroid dehydrogenase type 5. Molecular and Cellular Endocrinology. 2001;171(1–2):151–162
  53. Brozic P, Golob B, Gomboc N, et al. Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (akr1c3). Molecular and Cellular Endocrinology. 2006;248(1–2):233–235
  54. Simard J, Ricketts M-L, Gingras S, et al. Molecular biology of the 3{beta}-hydroxysteroid dehydrogenase/{delta}5-{delta}4 isomerase gene family. Endocrine Reviews. 2005;26(4):525–582
  55. Thomas JL, Boswell EL, Scaccia LA, et al. Identification of key amino acids responsible for the substantially higher affinities of human type 1 3{beta}-hydroxysteroid dehydrogenase/isomerase (3{beta}-HSD1) for substrates, coenzymes, and inhibitors relative to human 3{beta}-HSD2. The Journal of Biological Chemistry. 2005;280(22):21321–21328
  56. Makridakis N, Reichardt JK. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: Comparison of finasteride and dutasteride. Journal of Molecular Endocrinology. 2005;34(3):617–623
  57. Titus M, Li Y, Kawinski E, et al. Biochemical and pharmacological evidence for a third isozyme of steroid 5a-reductase in prostate cancer. American Urological Association, Anaheim (CA). 2007;268
  58. Stanway SJ, Purohit A, Woo LW, et al. Phase I study of STX 64 (667 coumate) in breast cancer patients: The first study of a steroid sulfatase inhibitor. Clinical Cancer Research. 2006;12(5):1585–1592
  59. Klein H, Molwitz T, Bartsch W. Steroid sulfate sulfatase in human benign prostatic hyperplasia: Characterization and quantification of the enzyme in epithelium and stroma. Journal of Steroid Biochemistry. 1989;33(2):195–200
  60. Nakamura Y, Suzuki T, Fukuda T, et al. Steroid sulfatase and estrogen sulfotransferase in human prostate cancer. Prostate. 2006;66(9):1005–1012
  61. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Research. 2004;64(24):9209–9216
  62. Singh P, Uzgare A, Litvinov I, et al. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocrine-Related Cancer. 2006;13(3):653–666

PII: S1521-690X(08)00004-3

doi: 10.1016/j.beem.2008.01.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 243-258 , April 2008

Article Tools

* Image Usage & Resolution